- Liraglutide activates parabrachial CGRP neurons required for aversion but not for anorexia or weight loss.
- GIPR agonism or ondansetron ameliorated liraglutide-induced conditioned taste avoidance and CGRP activation without altering acute feeding suppression.
- Aversive and anorexigenic effects are mediated by distinct neural mechanisms and can be separably manipulated; GIPR agonism reduces aversion while preserving metabolic benefits.
Mol Metab. 2026 Oct 6:102453. doi: 10.1016/j.molmet.2026.102453. Online ahead of print.
ABSTRACT
Incretin mimetics such as the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide cause decreased food intake, weight loss, and aversion. Here, we examined the extent to which parabrachial calcitonin gene-related peptide (CGRP) neurons contribute to these effects. Further, we assessed whether glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism alters liraglutide-induced behavior and CGRP neuron activity. We found that liraglutide activates parabrachial CGRP neurons and that this is required for liraglutide-induced aversion, but not anorexia or weight loss. Additionally, treatment with a GIPR agonist (GIPRA) or the well-established anti-emetic drug ondansetron ameliorated liraglutide-induced conditioned taste avoidance (CTA) and CGRP neuron activation without affecting acute liraglutide-induced feeding suppression. Taken together, our findings demonstrate that the aversive and anorexigenic effects of liraglutide are mediated by distinct neural mechanisms that can be separably manipulated. Our findings also highlight GIPR agonism as an emerging anti-aversive approach to GLP-1RA-induced malaise while maintaining the beneficial metabolic effects.
PMID:42838450 | DOI:10.1016/j.molmet.2026.102453
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
